Project Grant R41NS122545
Award Date 9/1/21
Completion Date 8/31/22
Dollars Obligated $1.3M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85718, USA
Similar Awards
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $650,079 Project Grant to Northeastern University under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports the development and optimization of novel small-molecule probes targeting the alpha9 nicotinic acetylcholine receptor (α9*-nAChR) subunit, with the goal of exploring its potential for pain management. The 5-year project aims to advance...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $407,113 to the University of California, Irvine under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 15, 2025, for an R21 exploratory research project extending through July 31, 2027. This project grant supports the development of novel KV7 channel modulators designed to mitigate chronic pain by preventing M-current suppression...
- This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
- This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...
- This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
- Federal Grant Award Summary RTI International received a $603,406 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 9, 2025, through April 30, 2027. The award supports development of GPR139 (G protein-coupled receptor 139) antagonist compounds for pain treatment. The project addresses the critical public health challenge of...
- Federal Grant Award Summary Renerva, Inc. received a $500,000 Project Grant award from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279), effective September 1, 2025 through August 31, 2026. The company is developing PNM-CAP, a biodegradable nerve capping device derived from porcine peripheral nerves designed to prevent painful neuroma formation following extremity amputations. The device features a neuro-inhibitory...
- Federal Project Grant Award Summary Function Therapeutics Inc. received a $499,863 Project Grant from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test novel therapeutic compounds for treating neuropathic pain. The award, effective September 11, 2025 through August 31, 2027, supports the synthesis and characterization of Parmodulins—a proprietary class of small molecules designed to allosterically...